Inclusion Criteria:

- Must be female with histologically confirmed breast cancer

- Stage II-IV disease

- ER and/or PR positive

- ECOG Performance Status 0-1

- Tumor must be present following core needle biopsy as determined by physical exam or
radiographic evaluation.

- Postmenopausal

- No prior treatment for current breast cancer. No other active malignancy is
allowed.Adequately treated basal cell, squamous cell skin cancer, in situ cervical
cancer, or any other cancer from which the patient has been disease-free for 5 years
is permitted. Biphosphonates and palliative radiation for bone metastasis is
permitted while on study.

- Hormone replacement therapy must be discontinued. It is not permitted during the time
on study.

Exclusion Criteria:

- Known history of aspirin or NSAID induced asthma, urticaria or allergic reactions; or
allergy to sulfonamides severe enough in nature to require emergency room treatment
or hospitalization.

- History of myocardial infarction or other thrombotic events.

- Inflammatory breast cancer (edema or ulceration of the skin of the breast).

- Significant renal dysfunction (serum creatinine > 1.5 x upper limit of normal).

- Significant hepatic dysfunction (serum bilirubin > 1.5 x upper limit of normal or
AST, ALT > 3 x upper limit of normal)

- ANC <1.5, platelets <100,000 K/uL, and hemoglobin < 9 g/dL.

- Use of other COX-2 inhibitors such as rofecoxib (Vioxx®, aspirin, trisalicylate
(Trilisate®), is not permitted during the time on study. No washout period is
required. Baby aspirin, 81 mg po daily, is permitted.

- Use of NSAID's such as ibuprofen (Advil® or Motrin®), naproxyn (Aleve® Naprosyn®, or
Anaprox®), etodolac (Lodine®), oxaprozin (Daypro®), difusanil (Dolobid®), nabumetone
(Relafin®), or tolmetin (Tolectin®) is not permitted during the time on study.